JP2023510746A5 - - Google Patents
Info
- Publication number
- JP2023510746A5 JP2023510746A5 JP2022541815A JP2022541815A JP2023510746A5 JP 2023510746 A5 JP2023510746 A5 JP 2023510746A5 JP 2022541815 A JP2022541815 A JP 2022541815A JP 2022541815 A JP2022541815 A JP 2022541815A JP 2023510746 A5 JP2023510746 A5 JP 2023510746A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- cancer
- compound
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959502P | 2020-01-10 | 2020-01-10 | |
| US62/959,502 | 2020-01-10 | ||
| PCT/US2021/012683 WO2021142247A1 (en) | 2020-01-10 | 2021-01-08 | Smarca2-vhl degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510746A JP2023510746A (ja) | 2023-03-15 |
| JP2023510746A5 true JP2023510746A5 (cg-RX-API-DMAC7.html) | 2024-01-16 |
| JP7706456B2 JP7706456B2 (ja) | 2025-07-11 |
Family
ID=74495106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541815A Active JP7706456B2 (ja) | 2020-01-10 | 2021-01-08 | Smarca2-vhl分解剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230091042A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087658B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7706456B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205326B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167166A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008487A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142247A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| MX2023001445A (es) * | 2020-08-04 | 2023-05-08 | Aurigene Oncology Ltd | Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| JP2024533990A (ja) | 2021-08-09 | 2024-09-18 | ジェネンテック, インコーポレイテッド | Brmの調節に使用するためのフェノール誘導体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| AU2019249849C1 (en) * | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
-
2021
- 2021-01-08 CA CA3167166A patent/CA3167166A1/en active Pending
- 2021-01-08 US US17/788,272 patent/US20230091042A1/en active Pending
- 2021-01-08 WO PCT/US2021/012683 patent/WO2021142247A1/en not_active Ceased
- 2021-01-08 JP JP2022541815A patent/JP7706456B2/ja active Active
- 2021-01-08 AU AU2021205326A patent/AU2021205326B2/en active Active
- 2021-01-08 MX MX2022008487A patent/MX2022008487A/es unknown
- 2021-01-08 EP EP21702829.9A patent/EP4087658B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW384288B (en) | 5-substituted derivatives of mycophenolic acid | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2010505930A5 (cg-RX-API-DMAC7.html) | ||
| JP2009507909A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508310A5 (cg-RX-API-DMAC7.html) | ||
| JP7205830B2 (ja) | 新規アントラニル酸系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP2006526590A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534264A5 (cg-RX-API-DMAC7.html) | ||
| JP2009538327A5 (cg-RX-API-DMAC7.html) | ||
| JP2024509981A5 (cg-RX-API-DMAC7.html) | ||
| JP2006501201A5 (cg-RX-API-DMAC7.html) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| US10172814B2 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| JP2007529426A5 (cg-RX-API-DMAC7.html) | ||
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP2013544794A5 (cg-RX-API-DMAC7.html) | ||
| WO2002006249A1 (en) | Method for producing 1-substituted-1,2,3-triazole derivative | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto | |
| CA3167918A1 (en) | Compositions and methods for modulating cancer | |
| TW422834B (en) | Butyrate prodrugs for increasing fetal hemoglobim and promoting cell differenfiation and pharmacentical compositions comprising the same | |
| JP2017513934A5 (cg-RX-API-DMAC7.html) | ||
| WO2002074296A1 (en) | Remedies for solid cancer containing hydroxamic acid derivatives as the active ingredient | |
| TW202340142A (zh) | Gcl抑制劑 | |
| JP2004528311A5 (cg-RX-API-DMAC7.html) | ||
| JP2023541840A5 (cg-RX-API-DMAC7.html) |